Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript

Page 7 of 7

Avanish Vellanki: Thanks, operator, and thanks to everyone that dialed into our call today. As a reminder, we expect top line data from the pivotal Phase 3 milademetan trial in Dedifferentiated liposarcoma in the second quarter of this year. We also anticipate the start of the Phase 1/2 Basket study, the MANTRA-4 study in patients with p53 wild type advanced solid tumors that have CD, that have lost CDKN2A gene function around middle of the year. So we believe this will be an exciting year for Rain and the mila program. We look forward to providing further update after the first quarter of 2023. Thank you.

Operator: Thank you. This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.

Follow Rain Oncology Inc.

Page 7 of 7